DBV Technologies (NASDAQ:DBVT) Now Covered by StockNews.com

Research analysts at StockNews.com assumed coverage on shares of DBV Technologies (NASDAQ:DBVT) in a research note issued on Saturday. The brokerage set a “hold” rating on the stock.

Separately, HC Wainwright reissued a “buy” rating and set a $10.00 price target on shares of DBV Technologies in a research report on Wednesday, February 21st.

DBV Technologies Price Performance

DBVT stock opened at $0.68 on Friday. The company has a 50 day moving average price of $0.79 and a 200 day moving average price of $0.89. DBV Technologies has a fifty-two week low of $0.65 and a fifty-two week high of $2.37. The stock has a market capitalization of $131.48 million, a PE ratio of -1.75 and a beta of 0.75.

DBV Technologies (NASDAQ:DBVT) last announced its quarterly earnings data on Thursday, March 7th. The company reported ($0.06) earnings per share for the quarter, topping the consensus estimate of ($0.16) by $0.10. DBV Technologies had a negative return on equity of 46.33% and a negative net margin of 461.32%. The firm had revenue of $8.88 million during the quarter, compared to analysts’ expectations of $1.10 million. During the same period in the previous year, the business posted ($0.23) EPS. As a group, equities analysts expect that DBV Technologies will post -0.88 earnings per share for the current fiscal year.

Institutional Trading of DBV Technologies

Several hedge funds have recently added to or reduced their stakes in DBVT. Commonwealth Equity Services LLC acquired a new stake in shares of DBV Technologies during the 3rd quarter worth $26,000. Goldman Sachs Group Inc. lifted its position in DBV Technologies by 225.0% during the fourth quarter. Goldman Sachs Group Inc. now owns 46,805 shares of the company’s stock worth $45,000 after purchasing an additional 32,405 shares during the period. Cowen AND Company LLC acquired a new stake in DBV Technologies during the fourth quarter worth about $49,000. BNP Paribas Arbitrage SA bought a new position in DBV Technologies in the 2nd quarter valued at about $49,000. Finally, OLD Mission Capital LLC raised its position in shares of DBV Technologies by 243.7% in the 1st quarter. OLD Mission Capital LLC now owns 30,597 shares of the company’s stock valued at $52,000 after buying an additional 21,694 shares in the last quarter. 71.74% of the stock is owned by institutional investors and hedge funds.

DBV Technologies Company Profile

DBV Technologies SA, a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow's milk protein allergy and eosinophilic esophagitis.